NASDAQ: TENX

TENAX THERAPEUTICS, INC.

CIK 0000034956 · Pharmaceutical Preparations

8-K Filed Jun 4, 2026 · Period ending Jun 2, 2026

Tenax Therapeutics holds routine annual meeting, elects seven directors for one-year terms

2 material changes detected. Sign up free to read the summary.

View report
10-Q Filed May 12, 2026 · Period ending Mar 31, 2026

TENX completes Phase 3 trial enrollment, extends cash runway to Q1 2028 on warrant proceeds

5 material changes detected. Sign up free to read the summary.

View report

Partner

Trade TENX commission-free

Open an account, get a free stock.

Sign up

Investing involves risk. Free stock terms apply.

8-K Filed May 12, 2026 · Period ending May 12, 2026

Tenax Therapeutics reports Q1 2026 financial results

2 material changes detected. Sign up free to read the summary.

View report
8-K Filed Apr 22, 2026 · Period ending Apr 22, 2026 Red flag

Tenax Therapeutics appoints Thomas R. Staab as CFO with $428K salary, 450K stock options

4 material changes detected. Sign up free to read the summary.

View report
10-K Filed Mar 10, 2026 · Period ending Dec 31, 2025

Summary not yet generated.

10-Q Filed Nov 12, 2025 · Period ending Sep 30, 2025

Summary not yet generated.

10-Q Filed May 14, 2025 · Period ending Mar 31, 2025

Summary not yet generated.

10-K Filed Mar 25, 2025 · Period ending Dec 31, 2024

Summary not yet generated.

View all filings for TENX on SEC EDGAR